Meta Expands AI Training With Employee Activity Tracking Tools 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
NEW YORK, March 04, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Esperion Therapeutics, Inc. securities (NASDAQ:ESPR) from August 18, 2015 through September 28, 2015, both dates inclusive (the “Class Period”) of the important March 14, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Esperion Therapeutics investors under the federal securities laws.
To join the Esperion Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-814.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period, Defendants issued materially false and misleading statements to investors and/or failed to disclose that there was no clear path to approval for ETC-1002, the FDA had encouraged Esperion Therapeutics to initiate a cardiovascular outcomes trial (“CVOT”) and completion of a CVOT could be necessary prior to approval of ETC-1002. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-814.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
